Veracyte director granted 5,272 RSU shares

EPSTEIN ROBERT S reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

EPSTEIN ROBERT S reported acquisition or exercise transactions in this Form 4 filing.

VERACYTE, INC. director Robert S. Epstein received an equity award in the form of 5,272 shares of common stock on June 11, 2026. The grant was made at a price of $0.00 per share as compensation rather than an open-market purchase. Following this award, Epstein directly holds 57,718 shares of Veracyte common stock. The underlying restricted stock units vest in full on the first anniversary of the grant date or immediately prior to the company’s next annual meeting of stockholders, if earlier, and they also vest in full upon a change in control of the issuer.

Insights

Equity Compensation Analyst

Director received time-based RSU award that vests over roughly one year.

This Form 4 shows Robert S. Epstein, a director of Veracyte, receiving 5,272 shares of common stock as a grant priced at $0.00 per share. This reflects standard equity compensation, not an open-market purchase.

The footnote states these restricted stock units vest in full on the first anniversary of the June 11, 2026 grant or immediately before the next annual stockholder meeting, and also upon a change in control. Such terms align board incentives with shareholder outcomes while keeping near-term dilution modest.

Insider Trade Summary

Grant/Award: 5,272 shares

Grant/Award 1 txn

Insider EPSTEIN ROBERT S

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,272	$0.00	$0.00

Holdings After Transaction: Common Stock — 57,718 shares (Direct)

Footnotes (1)

1. F1. Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.

Key Figures

Shares granted: 5,272 shares Price per share: $0.00 per share Holdings after transaction: 57,718 shares +2 more

5 metrics

Shares granted 5,272 shares Restricted stock unit award on June 11, 2026

Price per share $0.00 per share Equity grant, not open-market purchase

Holdings after transaction 57,718 shares Total common stock directly held after grant

Grant date June 11, 2026 Date restricted stock units were awarded

Vesting schedule Full vesting after ~1 year or earlier meeting First anniversary of grant or before next annual meeting

Key Terms

Restricted stock units, change in control, annual meeting of stockholders, Grant, award, or other acquisition

4 terms

Restricted stock units financial

"Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

change in control financial

"the restricted stock units vest in full in the event of a change in control of the Issuer"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

annual meeting of stockholders financial

"vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders"

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Veracyte (VCYT) director Robert S. Epstein report on this Form 4?

Robert S. Epstein reported receiving 5,272 shares of Veracyte common stock as an equity grant. The award was priced at $0.00 per share and increased his direct holdings to 57,718 shares, reflecting routine director compensation rather than an open-market stock purchase.

How many Veracyte (VCYT) shares did Robert S. Epstein acquire in this transaction?

He acquired 5,272 shares of Veracyte common stock through a grant. These shares stem from restricted stock units awarded on June 11, 2026, and are structured as compensation, not as a cash purchase on the open market by the director.

What are the vesting terms of Robert S. Epstein’s Veracyte (VCYT) restricted stock units?

The restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the grant or immediately before Veracyte’s next annual stockholder meeting, if earlier. They also fully vest if there is a change in control of the issuer.

How many Veracyte (VCYT) shares does Robert S. Epstein hold after this grant?

After this equity grant, Robert S. Epstein directly holds 57,718 shares of Veracyte common stock. This figure reflects his updated ownership position following receipt of 5,272 shares under the restricted stock unit award reported in the Form 4 filing.

Was cash paid for the Veracyte (VCYT) shares reported in this Form 4?

No cash was paid for these shares; the transaction price per share is reported as $0.00. The 5,272 shares were granted as equity compensation in the form of restricted stock units rather than purchased in an open-market transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 04:55 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EPSTEIN ROBERT S

(Last) (First) (Middle)

6000 SHORELINE COURT

SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A(1)		5,272	A	$0	57,718	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.

Remarks:

	/s/ Jonathan Wygant, as attorney-in-fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)